6:00 p.m. CET – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, today announces its financial calendar for the year 2023.
March 15, 2023 Publication of 2022 annual results
April 25, 2023 Publication of 1st quarter 2023 revenue
July 25, 2023 Publication of 2nd quarter 2023 revenue
September 18, 2023 Publication of half-year results as of June 30, 2023
October 25, 2023 Publication of 3rd quarter 2023 revenue
In addition to regular meetings with the financial community, investors are invited to consult the company’s website (www.adocia.com) whose information is regularly updated.
All “corporate” information available on the Company – such as its financial statements, its presentations to investors and its articles of association – is updated in the “Investors”, “Regulated Information” section of the Company’s website.